Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - loratadine - syrup - loratadine 0.1 g / 100 ml - loratadine - antihistamine preparation for treatment of allergic rhinitis and urticaria.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 150 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 150 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 300 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - film coated tablets - propafenone hydrochloride 300 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tolterodine l-tartrate - capsules slow release - tolterodine l-tartrate 4 mg - tolterodine - tolterodine - for the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tolterodine l-tartrate - capsules slow release - tolterodine l-tartrate 2 mg - tolterodine - tolterodine - for the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 150 mg - quetiapine - seroquel xr is indicated for the treatment of schizophrenia. seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians shoul